Maggie Cheang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11272071/publications.pdf

Version: 2024-02-01

1051969 1255698 3,964 13 10 13 citations g-index h-index papers 13 13 13 6400 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2â^' Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174.	3.2	8
2	Abstract PS5-01: Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial. Cancer Research, 2021, 81, PS5-01-PS5-01.	0.4	3
3	Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1443-1454.	5.1	159
4	Training and accreditation standards for pathologists undertaking clinical trial work. Journal of Pathology: Clinical Research, 2019, 5, 100-107.	1.3	10
5	The use of digital pathology and image analysis in clinical trials. Journal of Pathology: Clinical Research, 2019, 5, 81-90.	1.3	71
6	Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. Journal of Pathology: Clinical Research, 2019, 5, 91-99.	1.3	21
7	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine, 2015, 7, 302ra133.	5. 8	889
8	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Research and Treatment, 2012, 132, 131-142.	1.1	117
9	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. Modern Pathology, 2008, 21, 1413-1420.	2.9	3
10	GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 365-373.	1.1	125
11	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Research, 2005, 7, R796-807.	2.2	83
12	Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clinical Cancer Research, 2004, 10, 5367-5374.	3.2	2,393
13	Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival. Cancer Research, 2004, 64, 286-291.	0.4	82